FILE 02 / REGULATORY STATUS
Is BPC-157 legal? FDA, compounding and anti-doping status
Prepared by: Research Desk. Sources are linked for verification.
Contents
People asking “is BPC-157 legal?” usually mean one of three things. Can it be prescribed? Can it be sold? Is it banned in sport? Each has a different answer. This file sets out what we can document, with dates, and marks what we couldn’t confirm.
Exhibit A: it is not an FDA-approved drug
No BPC-157 product has been approved by the FDA for any use. A 2025 systematic review in orthopaedic sports medicine notes that it lacks FDA approval and that its use is banned in professional sports, yet it is increasingly used in sports-medicine settings and by athletes [1].
That’s the baseline. Everything else on this page concerns the narrower routes by which an unapproved substance can, or can’t, reach a person.
Exhibit B: FDA’s documented safety concerns (compounding)
Pharmacies may compound drugs from bulk substances only under specific conditions. FDA publishes a list of bulk substances nominated for compounding that it believes “may present significant safety risks” [2].
On the version we reviewed (content current as of 22 April 2026), BPC-157 appears in the section of substances that were previously in category 2 and whose nominations were then withdrawn by the nominators. FDA’s entry still records its concerns [2]:
“Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”
What “withdrawn” does and doesn’t mean: The nomination that placed BPC-157 in category 2 was pulled. That doesn’t mean FDA has decided BPC-157 is safe, and it doesn’t make BPC-157 an approved drug.
Exhibit C: the July 2026 advisory committee meeting
FDA’s Pharmacy Compounding Advisory Committee (PCAC) met on 23–24 July 2026. On 23 July it discussed BPC-157-related bulk substances (free base and acetate) being considered for the 503A bulks list, which governs what traditional compounding pharmacies may use [3]. The use FDA evaluated for BPC-157 was ulcerative colitis [3]. The same session covered KPV, TB-500 and MOTS-c [3].
Key points about how this process works:
Advisory committee votes are advice. FDA makes the final decision, often months later, through a formal process.
A listing applies to the specific use and route reviewed. It wouldn’t make BPC-157 an approved drug, and it wouldn’t cover, for example, use for tendon injuries.
We have not independently verified the committee’s vote outcome from an official FDA record. We’ll update this page with the official minutes once we’ve reviewed them.
Exhibit D: anti-doping, banned at all times
The World Anti-Doping Agency’s Prohibited List names BPC-157 explicitly under S0 Non-Approved Substances. This class is prohibited at all times, in and out of competition, and covers substances “with no current approval by any governmental regulatory health authority for human therapeutic use” [4]. Athletes subject to WADA-code testing can face sanctions for using it. The same list prohibits TB-500, under thymosin-β4 derivatives in S2 [4].
Exhibit E: “research use only” sellers
Many websites sell BPC-157 labelled “for research purposes only, not for human consumption”. That label doesn’t make the product a lawful drug or dietary supplement for people. No regulator has reviewed what’s in those vials. FDA’s concerns about impurities and API characterization [2] apply even more strongly to products made with no pharmacy oversight. A 2025 systematic review notes that adverse effects are possible “due to unregulated manufacturing, contamination, or unknown clinical safety” [1].
BPC Recover will never link to, rank or name sellers.
Is it legal to possess?
That depends on your country and sometimes your state, and it is a legal question beyond what we can verify. We don’t give legal advice. In the U.S., the issues FDA addresses are mostly about marketing, compounding and distribution, not individual possession.
Summary
Question
Answer (as of 18 Oct 2026)
FDA-approved for any use?
No [1]
FDA safety concerns documented?
Yes: immunogenicity, impurities, limited safety data [2]
Under review for compounding?
Discussed by FDA’s advisory committee on 23 July 2026 for ulcerative colitis; FDA decision pending our verification [3]
Allowed in WADA-tested sport?
No. Prohibited at all times (S0) [4]
Status checked: 18 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.